1. Home
  2. JBDI vs ENLV Comparison

JBDI vs ENLV Comparison

Compare JBDI & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JBDI
  • ENLV
  • Stock Information
  • Founded
  • JBDI 1983
  • ENLV 2005
  • Country
  • JBDI Singapore
  • ENLV Israel
  • Employees
  • JBDI N/A
  • ENLV N/A
  • Industry
  • JBDI
  • ENLV Biotechnology: Pharmaceutical Preparations
  • Sector
  • JBDI
  • ENLV Health Care
  • Exchange
  • JBDI Nasdaq
  • ENLV Nasdaq
  • Market Cap
  • JBDI 20.8M
  • ENLV 23.7M
  • IPO Year
  • JBDI 2024
  • ENLV 1995
  • Fundamental
  • Price
  • JBDI $1.03
  • ENLV $1.82
  • Analyst Decision
  • JBDI
  • ENLV Strong Buy
  • Analyst Count
  • JBDI 0
  • ENLV 2
  • Target Price
  • JBDI N/A
  • ENLV $10.00
  • AVG Volume (30 Days)
  • JBDI 22.0K
  • ENLV 555.5K
  • Earning Date
  • JBDI 01-01-0001
  • ENLV 08-29-2025
  • Dividend Yield
  • JBDI N/A
  • ENLV N/A
  • EPS Growth
  • JBDI N/A
  • ENLV N/A
  • EPS
  • JBDI N/A
  • ENLV N/A
  • Revenue
  • JBDI $9,017,000.00
  • ENLV N/A
  • Revenue This Year
  • JBDI N/A
  • ENLV N/A
  • Revenue Next Year
  • JBDI N/A
  • ENLV N/A
  • P/E Ratio
  • JBDI N/A
  • ENLV N/A
  • Revenue Growth
  • JBDI N/A
  • ENLV N/A
  • 52 Week Low
  • JBDI $0.49
  • ENLV $0.81
  • 52 Week High
  • JBDI $39.41
  • ENLV $2.10
  • Technical
  • Relative Strength Index (RSI)
  • JBDI N/A
  • ENLV 76.81
  • Support Level
  • JBDI N/A
  • ENLV $1.31
  • Resistance Level
  • JBDI N/A
  • ENLV $1.66
  • Average True Range (ATR)
  • JBDI 0.00
  • ENLV 0.18
  • MACD
  • JBDI 0.00
  • ENLV 0.04
  • Stochastic Oscillator
  • JBDI 0.00
  • ENLV 65.85

About JBDI JBDI Holdings Limited Ordinary Shares

JBDI Holdings Ltd is a supplier of Reconditioned and new Containers in Singapore. Its products include Reconditioned and new steel drums, plastic drums, carboys and IBCs.

About ENLV Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Share on Social Networks: